DermaTherapy is the first silk-like therapeutic bedding linens to receive FDA 510(k) clearance as a Class I medical device that helps to reduce the likelihood of patients developing pressure injuries. Nearly 4,000 patients were included in the evaluation of DermaTherapy on the rate of pressure injuries (PIs) in high-risk patients in the cardiovascular and surgical intensive care units at the University of Michigan hospital in Ann Arbor, MI.

According to the study, the 46% reduction of posterior PIs led to a potential cost savings for the health system of nearly US$ 4 million. The article states that “”‹cost”‹ ”‹savings”‹ ”‹more”‹ ”‹than”‹ ”‹covered”‹ ”‹the”‹ ”‹increased”‹ ”‹cost”‹ ”‹of”‹ ”‹the specialty”‹ ”‹linens.” In addition, Michigan Medicine’s laundry manager, Rolando Croocks, indicated in the article that the specialty linens have withstood “repeated use and laundering for three times longer than cotton linens.”

In the study, the researchers state: “Overall, we noted significant reductions in posterior PIs, supporting the theory that addressing microclimate can help reduce the occurrence of PIs.” DermaTherapy therapeutic bedding addresses the patient’s microclimate by reducing shear and friction and controlling moisture and heat.

With two US patents (US 7,816,288 and US 8,283,267) and two pending patents, the DermaTherapy system is comprised of a pillowcase, top flat sheet, bottom fitted sheet and underpad, all developed in partnership between Standard Textile Co., Inc. and Precision Fabrics Group. DermaTherapy is a registered trademark of Precision Fabrics Group, Inc.

DermaTherapy also has FDA clearance for use in the treatment of atopic dermatitis by patients who are susceptible to or may have mild atopic dermatitis, the most common form of eczema.

www.precisionfabrics.com

www.dermatherapy.standardtextile.com